bims-humivi Biomed News
on Human mito-nuclear genetic interplay
Issue of 2026–03–01
three papers selected by
Mariangela Santorsola, Università di Pavia



  1. Int J Mol Sci. 2026 Feb 12. pii: 1773. [Epub ahead of print]27(4):
      The accumulation of somatic mutations contributes to clonal evolution and biological properties of cancers. Acquired mutations in mitochondrial (mt)DNA have been studied, but with the exception of those in isocitrate dehydrogenase genes, no comprehensive assessment of mutations in nuclear mitochondrial genes has been reported in sequential glioblastoma (GBM). We obtained ten pairs of GBM samples at diagnosis (GBM-P) and at recurrence (GBM-R). Extracted DNA was subjected to whole exome and mtDNA sequencing. After filtering out germline variants, bioinformatics analysis was performed using a mitochondrial gene panel of 483 nuclear-encoded, and 37 mtDNA-encoded genes. Variant classification was performed using established clinical- and molecular criteria, integrating population-frequency data, bioinformatic predictions, functional evidence, segregation information, and curated entries from the Mitomap and ClinVar databases. Benign single nucleotide variants in mtDNA-encoded genes of RNR1, RNR2, ATP6, CYB, CO2, TV, ATP8, and ND2 were detected, which changed little over time. However, three variants in TI, ND5 and ND1 with possible or likely pathogenic significance were found in the GBM-R samples. In contrast, pathogenic or likely pathogenic variants in 29 nuclear genes were found in GBM-P and GBM-R samples. Not only the overall number, but also the number of protein-truncating variants in nuclear genes increased over time. Conclusions: This study sheds light on the accumulation of mutations in nuclear genes of mitochondrial proteins in sequential GBM samples. As such variants may influence metabolic, proliferative and invasive properties as well as the necrotic propensity of the tumor, a comprehensive analysis of these genes merits further studies.
    Keywords:  glioblastoma; mitochondrial DNA; next generation sequencing; nuclear-encoded mitochondrial protein genes
    DOI:  https://doi.org/10.3390/ijms27041773
  2. Biomedicines. 2026 Jan 30. pii: 313. [Epub ahead of print]14(2):
      Neurodegenerative diseases (NDs) are the most prevalent age-associated disorders, characterized by progressive neuronal loss and cognitive decline. Mitochondrial dysfunction is strictly associated with NDs and represent one of the hallmarks of these disorders, with neurological syndromes frequently representing the primary clinical manifestations of mitochondrial abnormalities. As central regulators of cellular bioenergetics, mitochondria play a pivotal role in both the physiological maintenance and pathogenesis of disease by different regulatory approaches. One of these, microRNAs (miRNAs), a class of small non-coding RNAs, are well-established regulators of gene expression across different biological pathways. These miRNAs were usually investigated within the cytoplasmic context, but recent discoveries have revealed the presence of these miRNAs in different parts of mitochondria, where they contribute to the regulation of gene expression and metabolic activity. These mitochondrial-localized miRNAs, termed mito-MiRNA, may originate from either nuclear or mitochondrial genomes and have been shown to modulate the translational machinery of the cells. Despite extensive research on cytoplasmic miRNAs, the functional roles of mito-MiRNA remain poorly understood, particularly in the context of neurodegenerative disorders. Based on these findings, this review aims to synthesize emerging evidence on the involvement of mito-MiRNA in in one of most prevalent neurodegenerative diseases-Parkinson's disease (PD).
    Keywords:  MiRNAs; Mito-MiRNA; Parkinson’s disease; agomir; antagomir; mitochondrial dysfunction
    DOI:  https://doi.org/10.3390/biomedicines14020313
  3. Genes (Basel). 2026 Jan 28. pii: 151. [Epub ahead of print]17(2):
      The increasing and global distribution of microplastics and nanoplastics (MPs/NPs) in the environment has led to concern about their potential influence on human health, especially on the gastrointestinal tract, as well as the brain. MPs/NPs could traverse epithelial and endothelial barriers, disrupt the gut microbiota, and perturb the microbiota-gut-brain axis, leading to systemic inflammation and possibly extending neurodegenerative processes. Experimental models now demonstrate that MPs/NPs reprogram nuclear and mitochondrial epigenetics-DNA methylation, histone modifications, non-coding RNAs, and mitochondrial DNA regulation-in gut, immune, and neural cells with downstream effects on synaptic function, neuronal survival, and protein aggregation. This mechanistic narrative review integrates preclinical and emerging human evidence of how MPs/NPs compromise intestinal barrier integrity, modulate gut microbiota composition, affect the blood-brain barrier, and converge on oxidative stress, neuroinflammatory signaling, and cell death pathways within the central nervous system across key neurodegenerative diseases. Overall, the review offers an integrated model in which environmental exposure to chronic MPs/NPs disrupts the microbiota-gut-brain axis and drives concurrent nuclear and mitochondrial epigenetic remodeling, lowering the threshold for neurodegeneration in susceptible individuals, while outlining candidate mechanistic readouts that require exposure-specific validation in human-relevant models and longitudinal cohorts.
    Keywords:  epigenetic mechanisms; gut–brain axis; microplastics; nanoplastics; neurodegeneration; neurotoxicity; plastics
    DOI:  https://doi.org/10.3390/genes17020151